---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044323"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:18:10.752235+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Imunon appoints Dr. Sébastien Hazard as EVP and Chief Medical Officer

## Summary
- Dr. Hazard joins as EVP and CMO effective Dec. 11, 2023; previously Head of Clinical Development at Bicycle Therapeutics.
- Base salary of $475,000, target bonus of 50%; received inducement option for 80,000 shares at $0.88/share and 20,000 restricted shares.
- He will oversee clinical programs including IMNN-001 (IL-2) for ovarian cancer; topline data from OVATION 2 Study expected Q2 2024.

## SEC filing metadata
- accession: 0001493152-23-044323
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315223044323/0001493152-23-044323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315223044323/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044323
- JSON: https://secwatch.observer/filing/0001493152-23-044323.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044323.txt

## Key facts
- Executive change
  Dr. Sébastien Hazard was appointed as Executive Vice President and Chief Medical Officer at Imunon, Inc..
  - Action: appointed
  - Role: Executive Vice President and Chief Medical Officer
  source text: On December 7, 2023, Imunon, Inc. (the “Company”) appointed Dr. Sébastien Hazard to the positions of Executive Vice President and Chief Medical Officer of the Company, effective as of December 11, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315223044323/0001493152-23-044323-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.